1. Severe, Intolerable Fatigue Associated with Hyperresponse to Clopidogrel
- Author
-
Kate T. Carroll, Rajeev Sen, Dominick J. Angiolillo, Marco Cattaneo, Min S. Park, David I. Bass, Michael J. Cruz, Christopher C. Young, Chungeun Lee, Louis J. Kim, Michael R. Levitt, and Kevin N. Vanent
- Subjects
Adult ,medicine.medical_specialty ,Platelet Function Tests ,Side effect ,Constitutional symptoms ,medicine.medical_treatment ,Neurosurgical Procedures ,Drug Hypersensitivity ,P2Y12 ,Internal medicine ,medicine ,Humans ,In patient ,Platelet ,cardiovascular diseases ,Fatigue ,Aged ,Retrospective Studies ,business.industry ,Endovascular Procedures ,Stent ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Clopidogrel ,Receptors, Purinergic P2Y12 ,Female ,Surgery ,Purinergic P2Y Receptor Agonists ,Neurology (clinical) ,business ,Platelet Aggregation Inhibitors ,circulatory and respiratory physiology ,medicine.drug - Abstract
Objective Clopidogrel is a commonly used antiplatelet agent for the prevention of thromboembolic complications following neuroendovascular procedures, but anecdotal data have raised concern for the possibility that clopidogrel may induce severe, intolerable fatigue. The purpose of this study is to systematically investigate this phenomenon. Methods We performed a dual-institution, 9-year, retrospective study of patients undergoing clopidogrel therapy for neuroendovascular procedures. Patients were included only if their response to clopidogrel was assessed by platelet function testing using the VerifyNow P2Y12 (VNP) assay. Hyperresponse to clopidogrel was defined as P2Y12 reaction units ≤60. Patients were considered to have had clopidogrel-induced severe fatigue if the onset of symptoms followed the initiation of clopidogrel therapy; symptoms improved following a reduction in the dose of clopidogrel; and symptoms could not be attributed to any other medical explanation. Results Data were collected on 349 patients. Five patients (1.4%) met criteria for clopidogrel-induced severe fatigue. All 5 patients were female, ages 39–68. VNP assessments obtained while patients were symptomatic revealed hyperresponse to clopidogrel (0–22 P2Y12 reaction units). Symptoms improved in all 5 patients when the dose of clopidogrel was reduced by half. Notably, 30% of patients (n = 103) demonstrated a hyperresponse to clopidogrel on at least 1 VNP assessment, but 98 of these patients did not suffer from severe fatigue. Conclusions A syndrome of severe fatigue and other constitutional symptoms is a rare but clinically significant side effect of hyperresponse to clopidogrel in patients undergoing neuroendovasular intervention.
- Published
- 2021